Human NOD2/ACUG/BLAU ORF/cDNA clone-Lentivirus particle (NM_022162)
Cat. No.: vGMLP002900
Pre-made Human NOD2/ACUG/BLAU Lentiviral expression plasmid for NOD2 lentivirus packaging, NOD2 lentivirus production, overexpression stable cell line development, cell transient transfection and gene delivery targeting T/B/NK cells, macrophages, cardiomyocytes, hepatocytes, and neurons.
The GM Vector Core (GMVC) specializes in custom lentivirus development and offers a range of lentivirus manufacturing solutions, leveraging state-of-the-art processes. Learn more about our services.
Go to
NOD2/ACUG products
collection>>
(antibodies,
antigen, VLP, mRNA, ORF viral vector, etc)
| Catalog No. | Product Name | lentivirus Grade | lentivirus quantity |
|---|---|---|---|
| vGMLP002900 | Human NOD2 Lentivirus particle | Pilot Grade | 1.0E+8TU |
| 5.0E+8TU | |||
| 1.0E+9TU | |||
| Research Grade | 1.0E+8TU | ||
| 5.0E+8TU | |||
| 1.0E+9TU | |||
| GMP-like Grade | inquiry | ||
| GMP Grade | inquiry |
Product Description
| Catalog ID | vGMLP002900 |
| Gene Name | NOD2 |
| Accession Number | NM_022162 |
| Gene ID | 64127 |
| Species | Human |
| Product Type | Lentivirus particle (overexpression) |
| Insert Length | 3123 bp |
| Gene Alias | ACUG,BLAU,BLAUS,CARD15,CD,CLR16.3,IBD1,NLRC2,NOD2B,PSORAS1,YAOS |
| Fluorescent Reporter | ZsGreen |
| Mammalian Cell Selection | Puromyocin |
| Fusion Tag | 3xflag (C-Terminal) |
| Promoter | CMV |
| Resistance | Amplicin |
| ORF Nucleotide Sequence | ATGGGGGAAGAGGGTGGTTCAGCCTCTCACGATGAGGAGGAAAGAGCAAGTGTCCTCCTCGGACATTCTCCGGGTTGTGAAATGTGCTCGCAGGAGGCTTTTCAGGCACAGAGGAGCCAGCTGGTCGAGCTGCTGGTCTCAGGGTCCCTGGAAGGCTTCGAGAGTGTCCTGGACTGGCTGCTGTCCTGGGAGGTCCTCTCCTGGGAGGACTACGAGGGCTTCCACCTCCTGGGCCAGCCTCTCTCCCACTTGGCCAGGCGCCTTCTGGACACCGTCTGGAATAAGGGTACTTGGGCCTGTCAGAAGCTCATCGCGGCTGCCCAAGAAGCCCAGGCCGACAGCCAGTCCCCCAAGCTGCATGGCTGCTGGGACCCCCACTCGCTCCACCCAGCCCGAGACCTGCAGAGTCACCGGCCAGCCATTGTCAGGAGGCTCCACAGCCATGTGGAGAACATGCTGGACCTGGCATGGGAGCGGGGTTTCGTCAGCCAGTATGAATGTGATGAAATCAGGTTGCCGATCTTCACACCGTCCCAGAGGGCAAGAAGGCTGCTTGATCTTGCCACGGTGAAAGCGAATGGATTGGCTGCCTTCCTTCTACAACATGTTCAGGAATTACCAGTCCCATTGGCCCTGCCTTTGGAAGCTGCCACATGCAAGAAGTATATGGCCAAGCTGAGGACCACGGTGTCTGCTCAGTCTCGCTTCCTCAGTACCTATGATGGAGCAGAGACGCTCTGCCTGGAGGACATATACACAGAGAATGTCCTGGAGGTCTGGGCAGATGTGGGCATGGCTGGACCCCCGCAGAAGAGCCCAGCCACCCTGGGCCTGGAGGAGCTCTTCAGCACCCCTGGCCACCTCAATGACGATGCGGACACTGTGCTGGTGGTGGGTGAGGCGGGCAGTGGCAAGAGCACGCTCCTGCAGCGGCTGCACTTGCTGTGGGCTGCAGGGCAAGACTTCCAGGAATTTCTCTTTGTCTTCCCATTCAGCTGCCGGCAGCTGCAGTGCATGGCCAAACCACTCTCTGTGCGGACTCTACTCTTTGAGCACTGCTGTTGGCCTGATGTTGGTCAAGAAGACATCTTCCAGTTACTCCTTGACCACCCTGACCGTGTCCTGTTAACCTTTGATGGCTTTGACGAGTTCAAGTTCAGGTTCACGGATCGTGAACGCCACTGCTCCCCGACCGACCCCACCTCTGTCCAGACCCTGCTCTTCAACCTTCTGCAGGGCAACCTGCTGAAGAATGCCCGCAAGGTGGTGACCAGCCGTCCGGCCGCTGTGTCGGCGTTCCTCAGGAAGTACATCCGCACCGAGTTCAACCTCAAGGGCTTCTCTGAACAGGGCATCGAGCTGTACCTGAGGAAGCGCCATCATGAGCCCGGGGTGGCGGACCGCCTCATCCGCCTGCTCCAAGAGACCTCAGCCCTGCACGGTTTGTGCCACCTGCCTGTCTTCTCATGGATGGTGTCCAAATGCCACCAGGAACTGTTGCTGCAGGAGGGGGGGTCCCCAAAGACCACTACAGATATGTACCTGCTGATTCTGCAGCATTTTCTGCTGCATGCCACCCCCCCAGACTCAGCTTCCCAAGGTCTGGGACCCAGTCTTCTTCGGGGCCGCCTCCCCACCCTCCTGCACCTGGGCAGACTGGCTCTGTGGGGCCTGGGCATGTGCTGCTACGTGTTCTCAGCCCAGCAGCTCCAGGCAGCACAGGTCAGCCCTGATGACATTTCTCTTGGCTTCCTGGTGCGTGCCAAAGGTGTCGTGCCAGGGAGTACGGCGCCCCTGGAATTCCTTCACATCACTTTCCAGTGCTTCTTTGCCGCGTTCTACCTGGCACTCAGTGCTGATGTGCCACCAGCTTTGCTCAGACACCTCTTCAATTGTGGCAGGCCAGGCAACTCACCAATGGCCAGGCTCCTGCCCACGATGTGCATCCAGGCCTCGGAGGGAAAGGACAGCAGCGTGGCAGCTTTGCTGCAGAAGGCCGAGCCGCACAACCTTCAGATCACAGCAGCCTTCCTGGCAGGGCTGTTGTCCCGGGAGCACTGGGGCCTGCTGGCTGAGTGCCAGACATCTGAGAAGGCCCTGCTCCGGCGCCAGGCCTGTGCCCGCTGGTGTCTGGCCCGCAGCCTCCGCAAGCACTTCCACTCCATCCCGCCAGCTGCACCGGGTGAGGCCAAGAGCGTGCATGCCATGCCCGGGTTCATCTGGCTCATCCGGAGCCTGTACGAGATGCAGGAGGAGCGGCTGGCTCGGAAGGCTGCACGTGGCCTGAATGTTGGGCACCTCAAGTTGACATTTTGCAGTGTGGGCCCCACTGAGTGTGCTGCCCTGGCCTTTGTGCTGCAGCACCTCCGGCGGCCCGTGGCCCTGCAGCTGGACTACAACTCTGTGGGTGACATTGGCGTGGAGCAGCTGCTGCCTTGCCTTGGTGTCTGCAAGGCTCTGTATTTGCGCGATAACAATATCTCAGACCGAGGCATCTGCAAGCTCATTGAATGTGCTCTTCACTGCGAGCAATTGCAGAAGTTAGCTCTATTCAACAACAAATTGACTGACGGCTGTGCACACTCCATGGCTAAGCTCCTTGCATGCAGGCAGAACTTCTTGGCATTGAGGCTGGGGAATAACTACATCACTGCCGCGGGAGCCCAAGTGCTGGCCGAGGGGCTCCGAGGCAACACCTCCTTGCAGTTCCTGGGATTCTGGGGCAACAGAGTGGGTGACGAGGGGGCCCAGGCCCTGGCTGAAGCCTTGGGTGATCACCAGAGCTTGAGGTGGCTCAGCCTGGTGGGGAACAACATTGGCAGTGTGGGTGCCCAAGCCTTGGCACTGATGCTGGCAAAGAACGTCATGCTAGAAGAACTCTGCCTGGAGGAGAACCATCTCCAGGATGAAGGTGTATGTTCTCTCGCAGAAGGACTGAAGAAAAATTCAAGTTTGAAAATCCTGAAGTTGTCCAATAACTGCATCACCTACCTAGGGGCAGAAGCCCTCCTGCAGGCCCTTGAAAGGAATGACACCATCCTGGAAGTCTGGCTCCGAGGGAACACTTTCTCTCTAGAGGAGGTTGACAAGCTCGGCTGCAGGGACACCAGACTCTTGCTTTGA |
| ORF Protein Sequence | MGEEGGSASHDEEERASVLLGHSPGCEMCSQEAFQAQRSQLVELLVSGSLEGFESVLDWLLSWEVLSWEDYEGFHLLGQPLSHLARRLLDTVWNKGTWACQKLIAAAQEAQADSQSPKLHGCWDPHSLHPARDLQSHRPAIVRRLHSHVENMLDLAWERGFVSQYECDEIRLPIFTPSQRARRLLDLATVKANGLAAFLLQHVQELPVPLALPLEAATCKKYMAKLRTTVSAQSRFLSTYDGAETLCLEDIYTENVLEVWADVGMAGPPQKSPATLGLEELFSTPGHLNDDADTVLVVGEAGSGKSTLLQRLHLLWAAGQDFQEFLFVFPFSCRQLQCMAKPLSVRTLLFEHCCWPDVGQEDIFQLLLDHPDRVLLTFDGFDEFKFRFTDRERHCSPTDPTSVQTLLFNLLQGNLLKNARKVVTSRPAAVSAFLRKYIRTEFNLKGFSEQGIELYLRKRHHEPGVADRLIRLLQETSALHGLCHLPVFSWMVSKCHQELLLQEGGSPKTTTDMYLLILQHFLLHATPPDSASQGLGPSLLRGRLPTLLHLGRLALWGLGMCCYVFSAQQLQAAQVSPDDISLGFLVRAKGVVPGSTAPLEFLHITFQCFFAAFYLALSADVPPALLRHLFNCGRPGNSPMARLLPTMCIQASEGKDSSVAALLQKAEPHNLQITAAFLAGLLSREHWGLLAECQTSEKALLRRQACARWCLARSLRKHFHSIPPAAPGEAKSVHAMPGFIWLIRSLYEMQEERLARKAARGLNVGHLKLTFCSVGPTECAALAFVLQHLRRPVALQLDYNSVGDIGVEQLLPCLGVCKALYLRDNNISDRGICKLIECALHCEQLQKLALFNNKLTDGCAHSMAKLLACRQNFLALRLGNNYITAAGAQVLAEGLRGNTSLQFLGFWGNRVGDEGAQALAEALGDHQSLRWLSLVGNNIGSVGAQALALMLAKNVMLEELCLEENHLQDEGVCSLAEGLKKNSSLKILKLSNNCITYLGAEALLQALERNDTILEVWLRGNTFSLEEVDKLGCRDTRLLL |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
| Category | Cat No. | Products Name |
|---|---|---|
| Target Antibody | GM-Tg-g-T75643-Ab | Anti-NOD2 monoclonal antibody |
| Target Antigen | GM-Tg-g-T75643-Ag | NOD2 protein |
| ORF Viral Vector | pGMLP002900 | Human NOD2 Lentivirus plasmid |
| ORF Viral Vector | pGMPC000815 | Human NOD2 Mammalian (Non-Viral Vector) plasmid |
| ORF Viral Vector | vGMLP002900 | Human NOD2 Lentivirus particle |
Target information
| Target ID | GM-T75643 |
| Target Name | NOD2 |
|
Gene Group Identifier (Target Gene ID in Homo species) |
64127 |
| Gene ID |
100059123 (Equus caballus), 101096863 (Felis catus), 257632 (Mus musculus), 291912 (Rattus norvegicus) 444867 (Bos taurus), 487286 (Canis lupus familiaris), 64127 (Homo sapiens), 695542 (Macaca mulatta) |
| Gene Symbols & Synonyms | NOD2,Nod2,CD,ACUG,BLAU,IBD1,Nlrc2,Card15,F830032C23Rik,CARD15,YAOS,BLAUS,NLRC2,NOD2B,CLR16.3,PSORAS1 |
| Target Alternative Names | ACUG,BLAU,BLAUS,CARD15,CD,CLR16.3,Card15,Caspase recruitment domain-containing protein 15,F830032C23Rik,IBD1,Inflammatory bowel disease protein 1,NLRC2,NOD2,NOD2B,Nlrc2,Nod2,Nucleotide-binding oligomerization domain-containing protein 2,PSORAS1,YAOS |
| Uniprot Accession |
Q6E804,Q8K3Z0,Q9HC29
Additional SwissProt Accessions: Q8K3Z0,Q6E804,Q9HC29 |
| Uniprot Entry Name | |
| Protein Sub-location | Introcelluar Protein |
| Category | Therapeutics Target |
| Disease | cancer |
| Disease from KEGG | NOD-like receptor signaling pathway, TNF signaling pathway, Tuberculosis, Inflammatory bowel disease |
| Gene Ensembl | ENSECAG00000017005, ENSMUSG00000055994, ENSBTAG00000020936, ENSCAFG00845003875, ENSG00000167207, ENSMMUG00000012207 |
| Target Classification | Tumor-associated antigen (TAA) |
About GMVC

GMVC (GM Vector Core) is GeneMedi’s unique platform for QbD Viral vectors Processes development and manufacturing. In GMVC, our core expertise lies in the tailored production of viral vectors, including adeno-associated virus (AAV), lentivirus, and adenovirus. Our state-of-the-art facilities are equipped for scalable manufacturing, ensuring high-quality viral vector production to meet both research and therapeutic needs. Our expert team specializes in process development, leveraging innovative technology and extensive industry knowledge to provide clients with tailored solutions that exceed expectations. GMVC will be the ideal partner for scientists and healthcare professionals seeking reliable and efficient viral vector production services.


